XML 50 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1
EQUITY (Tables)
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
SCHEDULE OF EXERCISE OF WARRANTS AND PRE FUNDED WARRANTS

SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK

As of December 31, 2024, the Company has outstanding warrants to purchase an aggregate of 40,268,464 shares of common stock as follows:

 

   Number of
underlying
Common stock
   Exercise price   Expiration date
Series F Warrants   433,878   $7.4250   June 5, 2025-October 16, 2025
Series G Warrants   1,092,344   $10.230   February 8, 2026
Series I Warrants   12,914,078   $1.3827   -*
Series J Warrants   12,914,086   $1.3827   -*
Series K Warrants   12,914,078   $1.3827   -*
Total Warrants   40,268,464         

 

  *

The Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval from the Food and Drug Administration (“FDA”) for the CGuard Prime Carotid Stent System (135 cm), (B) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (C) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins.

     
    During the years ended December 31, 2024 and 2023, a total of 213,458 and 54,135 warrants expired, respectively.
SCHEDULE OF STOCK OPTIONS GRANTED

 

   Year ended December 31 
   2024   2023 
       Weighted       Weighted 
   Number of options

 

 

  average

exercise price

   Number of options   average

exercise price

 
Outstanding - beginning of the year   1,379,696    2.58    294,712    5.21 
Granted   777,761    3.07    1,097,250    1.89 
Forfeited   (3,314)   3.54    (12,266)   4.00 
Outstanding- end of period   2,154,143    2.76    1,379,696    2.58 
Exercisable at the end of the year   644,882    3.36    215,709    5.38 

 

 

INSPIREMD, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

 

  4) The following table summarizes information about stock options granted to non-employees:

 

   Year ended December 31 
   2024   2023 
       Weighted       Weighted 
   Number of options

 

 

  average

exercise price

   Number of options   average

exercise price

 
Outstanding - beginning of the year   791,669    2.06    166,669    3.37 
Granted   125,000    2.37    625,000    1.71 
Outstanding - end of period   916,669    2.10    791,669    2.06 
Exercisable at the end of the year   387,333    2.37    84,667    3.42 
SCHEDULE OF RESTRICTED STOCK GRANTED TO EMPLOYEES
   Year ended December 31 
   2024   2023 
   Number of restricted stock 
Outstanding - beginning of the year   3,054,086    355,951 
Granted   2,217,966    2,914,340 
Forfeited   (128,660)   (29,695)
Vested   (1,069,428)   (186,510)
Outstanding - end of the year   4,073,964    3,054,086 
SCHEDULE OF RESTRICTED STOCK UNIT GRANTED TO EMPLOYEES
   Year ended December 31 
   2024   2023 
   Number of RSUs 
Outstanding - beginning of the year   1,282,228    237,078 
Granted   563,499    1,045,150 
Outstanding - end of the year   1,845,727    1,282,228 
SCHEDULE OF ADDITIONAL INFORMATION ABOUT ALL OPTIONS OUTSTANDING AND EXERCISABLE

   Outstanding as of December 31, 2024 

Exercise

price

  Options outstanding   Weighted average remaining contractual life (years)   Options exercisable 
$1.15-3.14   2,686,358    8.56    704,641 
$3.30-4.12   227,932    7.53    171,052 
$4.95-10.05   152,469    6.00    152,469 
$16.50   4,087    5.01    4,053 
    3,070,846    8.35    1,032,215 
SCHEDULE OF FAIR VALUE OF OPTIONS GRANTED TO EMPLOYEES
    Year ended December 31 
    2024    2023 
Expected life   5.125-10 years    5.125-6.5 years 
Risk-free interest rates   3.93%-4.44%    3.58%-4.73% 
Volatility   91.82%-119.38%    109.62%-125.61% 
Dividend yield   -    - 
SCHEDULE OF ALLOCATION OF TOTAL SHARE-BASED COMPENSATION EXPENSE
   Year ended December 31 
   2024   2023 
   ($ in thousands) 
Cost of revenues  $256   $93 
Research and development   2,412    649 
Sales and marketing   1,025    416 
General and administrative   6,445    3,332 
   $10,138   $4,490